RxDoctor Payments Data

Mussarat Tahira, MD

Internal Medicine · Arlington, VANPI 1235229519

Payments from drug & device makers

$2,107in general payments, 2019–2025

Across 107 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$406
  • Astellas Pharma US Inc$263
  • Johnson & Johnson$253
  • Amgen$148
  • AstraZeneca$139
  • GSK$136
  • plus $762 from 16 others

What the payments were for

  • Food & beverage$1,91591%
  • Education$1929%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,107 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$289,230
Medicare patients
389
Services billed
2,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$54,090
JardianceEmpagliflozin39$40,577
JanuviaSitagliptin Phosphate25$34,609
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,668
MyrbetriqMirabegron24$18,374
Breo ElliptaFluticasone/Vilanterol23$8,773
XareltoRivaroxaban11$8,600
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,225
Atorvastatin Calcium295$2,671
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,349
Mirtazapine51$1,269
Nifedipine ErNifedipine37$1,250
Pantoprazole Sodium106$1,232
Amlodipine Besylate202$1,227
Valsartan22$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$406$54,09050 claims
GSKTrelegy Ellipta, Breo Ellipta$136$27,44146 claims
Astellas Pharma US IncMyrbetriq$263$18,37424 claims
Johnson & JohnsonXarelto$253$8,60011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →